Transpara

ScreenPoint Medical
Transpara provides decision support during reading of 2D Full-Field Digital Mammography (FFDM) and 3D Digital Breast Tomosynthetis (DBT) to help improve clinical accuracy, reduce workload and optimize workflow. Transpara is intended to support healthcare professionals with detection and diagnosis of breast lesions or for assessment of breast density and breast cancer risk using radiological images of the breast.
screenpoint-transpara.png
Information source: Vendor
Last updated: March 24, 2024

General Information

General
Product name Transpara
Company ScreenPoint Medical
Subspeciality Breast
Modality Mammography
Disease targeted Breast cancer
Key-features Detection Aid, Region Analysis, Exam Score, Risk score
Suggested use Before: stratifying reading process (non, single, double read), adapting worklist order
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand)

Technical Specifications

Data characteristics
Population Asymptomatic women
Input 2D Full-Field Digital Mammography, 3D Digital Breast Tomosynthesis
Input format DICOM
Output Region findings, region scores and an exam score
Output format DICOM Mammography CAD Structured Report
Technology
Integration Integration in standard reading environment (PACS), Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker)
Trigger for analysis Automatically, right after the image acquisition
Processing time 1 - 10 minutes

Regulatory

Certification
CE
Certified, Class IIb , MDR
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)

Market

Market presence
On market since 09-2015
Distribution channels Incepto Medical, Volpara Health, Siemens Healthineers, Agfa Healthcare, Fujifilm, Human Bytes, Sectra Amplifier Store, Aidoc aiOS, Fomei and Medical Solutions, Calantic
Countries present (clinical, non-research use) 30+
Paying clinical customers (institutes) Non-disclosed
Research/test users (institutes) Non-disclosed
Pricing
Pricing model
Based on

Evidence

Evidence
Peer reviewed papers on performance

  • Transpara 2D, 1.7.0: AI performance by mammographic density in a retrospective cohort study of 99,489 participants in BreastScreen Norway (read)

  • Transpara 2D, 1.7.0: Breast cancer detection accuracy of AI in an entire screening population: a retrospective, multicentre study (read)

  • Transpara 2D, 1.7.0: Impact of real-life use of artificial intelligence as support for human reading in a population-based breast cancer screening program with mammography and tomosynthesis (read)

  • Transpara 2D, 1.7.0: AI Risk Score on Screening Mammograms Preceding Breast Cancer Diagnosis (read)

  • Transpara 2D, 1.7.0: Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study (read)

  • Transpara 2D, 1.7.0: Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases (read)

  • Transpara 2D, 1.7.0: Multi-modal artificial intelligence for the combination of automated 3D breast ultrasound and mammograms in a population of women with predominantly dense breasts (read)

  • Transpara 2D, 1.7.0: Artificial Intelligence Evaluation of 122 969 Mammography Examinations from a Population-based Screening Program (read)

  • Transpara 2D+3D, 1.7.0: Stand-Alone Use of Artificial Intelligence for Digital Mammography and Digital Breast Tomosynthesis Screening : A Retrospective Evaluation (read)

  • Transpara 3D, 1.7.0: AI Detection of Missed Cancers on Digital Mammography That Were Detected on Digital Breast Tomosynthesis (read)

  • Transpara 3D, 1.6.0: Impact of Artificial Intelligence Decision Support Using Deep Learning on Breast Cancer Screening Interpretation with Single-View Wide-Angle Digital Breast Tomosynthesis (read)

  • Transpara 2D+3D, 1.6.0: AI-based Strategies to Reduce Workload in Breast Cancer Screening with Mammography and Tomosynthesis: A Retrospective Evaluation (read)

  • Transpara 3D, 1.6.0: Impact of artificial intelligence support on accuracy and reading time in breast tomosynthesis image interpretation: a multi-reader multi-case study (read)

  • Transpara 2D, 1.5.0: Can artificial intelligence reduce the interval cancer rate in mammography screening? (read)

  • Transpara 2D, 1.3.0: Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women Breast Cancer (read)

  • Transpara 2D, 1.4.0: Identifying normal mammograms in a large screening population using artificial intelligence (read)

  • Transpara 2D, 1.4.0: Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study (read)

  • Transpara 2D, 1.3.0: Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System (read)

  • Transpara 2D, 1.4.0: Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists (read)

  • All papers can be found here.
Non-peer reviewed papers on performance
Other relevant papers

  • Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture (read)

  • Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer (read)

  • Computer-aided Detection of Masses at Mammography: Interactive Decision Support versus Prompts (read)

  • Standalone computer-aided detection compared to radiologists' performance for the detection of mammographic masses (read)

  • Using Computer Aided Detection in Mammography as a Decision Support (read)